- Home
- PLBC vs RIGL Comparison
PLBC vs RIGL Comparison
Compare PLBC & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLBC | RIGL |
|---|---|---|
| Founded | 1980 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 426.2M | 884.9M |
| IPO Year | 2002 | 2000 |
Fundamental Metrics
Financial Performance| Metric | PLBC | RIGL |
|---|---|---|
| Price | $61.81 | $48.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $67.33 | $63.00 |
| AVG Volume (30 Days) | 33.1K | ★ 237.4K |
| Earning Date | 10-23-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.17% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | ★ 2.79 | 1.32 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | $17.11 | $3.89 |
| Revenue Next Year | $3.75 | $21.95 |
| P/E Ratio | ★ $21.82 | $37.25 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $39.89 | $24.84 |
| 52 Week High | $64.00 | $52.24 |
Technical Indicators
Market Signals| Indicator | PLBC | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 52.74 | 57.86 |
| Support Level | $60.10 | $33.93 |
| Resistance Level | $63.47 | $49.50 |
| Average True Range (ATR) | 1.21 | 1.83 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 80.43 | 69.27 |
Price Performance
Historical ComparisonAbout PLBC Plumas Bancorp
Plumas Bancorp provides banking products and services in Northeastern California and Northwestern Nevada, offering a range of deposit products for commercial and retail customers, including checking, savings, money market accounts, time deposits, retirement accounts, and sweep accounts for businesses and public entities, along with digital banking services such as mobile and internet banking, remote deposit, and electronic funds transfers, as well as other customary banking services. Its loan portfolio comprises commercial real estate, commercial and industrial, consumer, agricultural, residential real estate, and construction and land development loans, and the company generates its revenue from loans and investment securities, with additional income from service fees.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.